Back to News
Oct 14, 2025 4:00 AM

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise.

Q3 2025 Highlights

Q3 2025 unaudited group revenue of approximately $206 million, up 53% year-over-year.

FY 2025 revenue guidance increased to $800 million to $820 million1.

Gozellix® now fully reimbursed by Centers for Medicare and Medicaid Services (CMS): Level II HCPCS2 code and Transitional Pass-Through (TPT) payment status effective 1 October 20253.

Illuccix® now approved in 19 European markets4 and the United Kingdom (UK); commercial launch has commenced in the UK, Germany, France, Finland, Sweden, Norway and Denmark. 

First patients dosed in the BiPASS™ trial of MRI + PSMA-PET5 for the diagnosis and detection of prostate cancer.

ProstACT® Global Phase 3 trial, Part 2 open for enrollment in Australia, New Zealand and Canada and study approved to commence in China, Singapore, Türkiye and Japan. Part 1 preliminary readout of safety profile and dosimetry to follow completion of patient monitoring and data analysis.

Q3 2025 Revenue (Unaudited)

Revenue US$M

Q3 2025

Q3 2024

Variation

Q2 2025

Variation

Group revenue

206

135

53%

204

1%

PSMA imaging revenue6

155

132

17%

154

1%

RLS third-party revenue7

47





46

2%

 Commentary and business highlights

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, "We believe this is a ...